Erasmus School of Health Policy & Management
Visiting fellow | Health Technology Assessment (HTA)
- knies@eshpm.eur.nl
More information
Work
- Jamie Elvidge, Nick Crabb, Diana Delnoij, Saskia Knies, Douglas Lundin, François Houÿez, Juha Röning, Junfeng Wang, Li Jiu, Alastair Bennett, Yingying Zhang & Dalia Dawoud (2024) - Implementing a sandbox approach in health technology assessment: Benefits and recommendations - International Journal of Technology Assessment in Health Care, 40 (1) - doi: 10.1017/S0266462324000412 - [link]
- Anne de Bruijn, Mats van Don, Saskia Knies, Werner Brouwer & Vivian Reckers-Droog (2024) - Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision - PharmacoEconomics, 42 (8), 879-894 - doi: 10.1007/s40273-024-01386-8 - [link]
- Xinyu Li, Rudolf Hoogenveen, Mohamed El Alili, Saskia Knies, Junfeng Wang, Joline W.J. Beulens, Petra J.M. Elders, Giel Nijpels, Anoukh van Giessen & Talitha L. Feenstra (2023) - Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry - PharmacoEconomics, 41 (10), 1249-1262 - doi: 10.1007/s40273-023-01286-3 - [link]
- , Joost J. Enzing, Frédérique C.W. van Krugten, Iryna Sabat, Sebastian Neumann-Böhme, Bert Boer, Saskia Knies & Werner B.F. Brouwer (2022) - Psychometric evaluation of the Mental Health Quality of Life (MHQoL) instrument in seven European countries - Health and Quality of Life Outcomes, 20 (1) - doi: 10.1186/s12955-022-02041-6 - [link]
- Joost J. Enzing, Saskia Knies, Jop Engel, Maarten J. IJzerman, Beate Sander, Rick Vreman, Bert Boer & Werner B.F. Brouwer (2022) - Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price?: A study of reimbursement reports - Cost Effectiveness and Resource Allocation, 20 (1) - doi: 10.1186/s12962-022-00383-y - [link]
- Joost J. Enzing, Sebastian Himmler, Saskia Knies & Werner B.F. Brouwer (2022) - Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions?: A Discrete Choice Experiment Among Dutch Healthcare Decision Makers - Value in Health, 25 (2), 222-229 - doi: 10.1016/j.jval.2021.08.007 - [link]
- Joost J Enzing, Saskia Knies, Bert Boer & Werner B F Brouwer (2021) - Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride? - Health Economics, Policy and Law, 16 (4), 440-456 - doi: 10.1017/s1744133120000237 - [link]
- Rick A. Vreman, Joost W. Geenen, Saskia Knies, Aukje K. Mantel-Teeuwisse, Hubert G.M. Leufkens & Wim G. Goettsch (2021) - Comment on “Deterministic Sensitivity Analysis Under Ignorance” - PharmacoEconomics, 39 (10), 1199 - doi: 10.1007/s40273-021-01086-7 - [link]
- Joost Enzing, Sylvia Vijgen, Saskia Knies, Bert Boer & Werner Brouwer (2021) - Do economic evaluations of TAVI deal with learning effects, innovation, and context dependency? A review - Health Policy and Technology, 10 (1), 111-119 - doi: 10.1016/j.hlpt.2020.09.006 - [link]
- TL (Talitha) Feenstra, Saskia Knies, BLT Ramaekers & H Koffijberg (2020) - Gezondheids-economische beslismodellen: de stand van zaken en de toekomst - VGE Bulletin, 24-27
- RA Vreman, JW Geenen, Saskia Knies, AK Mantel-Teeuwisse, HGM Leufkens & WG Goettsch (2020) - The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. - Pharmacoeconomics (Print) - doi: 10.1007/s40273-020-00979-3
- E Fenwick, L Steuten, Saskia Knies, S Ghabri, A Basu, JF Murray, HE Koffijberg, M Strong, GD Sanders Schmidler & C Rothery (2020) - Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. - Value in Health, 23 (2), 139-150 - doi: 10.1016/j.jval.2020.01.001.
- C Rothery, M Strong, HE Koffijberg, A Basu, S Ghabri, Saskia Knies, JF Murray, GD Sanders Schmidler, L Steuten & E Fenwick (2020) - Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. - Value in Health, 23 (3), 277-286 - doi: 10.1016/j.jval.2020.01.004
- SE Grimm, X Pouwels, BLT Ramaekers, B Wijnen, Saskia Knies, J Grutters & MA Joore (2019) - Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. - Pharmacoeconomics (Print) - doi: 10.1007/s40273-019-00855-9.
- Saskia Knies, Hans Severens & Werner Brouwer (2019) - Integrating clinical and economic evidence in clinical guidelines: More needed than ever! - Journal of Evaluation in Clinical Practice, 25 (4), 561-564 - doi: 10.1111/jep.12936 - [link]
- H Koffijberg & Saskia Knies (2018) - The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis. - Value in Health, 21 (2), 203-209 - doi: 10.1016/j.jval.2017.04.011
- Matthijs Versteegh, Saskia Knies & Werner Brouwer (2016) - From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare - Pharmacoeconomics (Print), 34 (11), 1071-1074 - doi: 10.1007/s40273-016-0431-y - [link]
- Olena Mandrik, Saskia Knies, O Golubovska, O Duda, L Dudar, S Fedorchenko, O Zaliska & Hans Severens (2015) - Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine - Open medicine, 10 (1), 25-33 - doi: 10.1515/med-2015-0006 - [link]
- Olena Mandrik, Isaac Corro Ramos, Saskia Knies, Maiwenn Al & Hans Severens (2015) - Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine - Cancer Management and Research (online), 2015 (7), 279-289 - doi: 10.2147/CMAR.S79258 - [link]
